Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 10/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 10/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 10/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 1.00 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trichostatin SCHEMBL446807 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| Trichostatin SCHEMBL19886 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| Trichostatin SCHEMBL446806 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| Trichostatin SCHEMBL16380793 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| Trichostatin SCHEMBL29450582 | 0.99 | HDAC1 (0.97) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL21965902 | 0.91 | HDAC1 (0.83) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10324242 | 0.90 | HDAC1 (0.81) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL17119540 | 0.88 | HDAC1 (0.79) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL14392626 | 0.87 | HDAC1 (0.77) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL13301372 | 0.87 | HDAC1 (0.77) | HDAC1HDAC6HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9693994-B2 | Class IIa HDAC inhibitors for the treatment of infection | RESEARCH DEVELOPMENT FOUNDATION (US) | 2017-07-04 | — | — | US | claimed |
| US-20150290168-A1 | CLASS IIA HDAC INHIBITORS FOR THE TREATMENT OF INFECTION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2015-10-15 | — | — | US | claimed |
| US-8524762-B2 | Thioxanthone-based autophagy inhibitor therapies to treat cancer | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | claimed |
| EP-2544673-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | Spectrum Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| EP-2217240-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | Agency for Science, Technology And Research (SG) | 2010-08-18 | — | — | EP | claimed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | claimed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | claimed |
| WO-2009058102-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-05-07 | — | — | WO | claimed |
| US-12606829-B2 | Compositions for herpesvirus transcriptional feedback circuit disruption and uses thereof | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240401150-A1 | PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240043934-A1 | PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF | THE BROAD INSTITUTE, INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2023164605-A2 | PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-4200446-A1 | PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF | The Broad Institute, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20100317739-A1 | HISTONE DEACETYLASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-16 | — | — | US | disclosed |
| EP-2231596-A1 | HISTONE DEACETYLASE INHIBITORS | Georgetown University (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009079375-A1 | HISTONE DEACETYLASE INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | HDAC1 1/4885HDAC6 10/4885HDAC3 9/4885 |
| US-20100317739-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC2 | HDAC1 1/4885HDAC6 10/4885HDAC3 5/4885 |
| US-12606829-B2 | Compositions for herpesvirus transcriptional feedback circuit disruption and uses thereof | IRF3, CBFB, STAT1 | HDAC1 2084/4885HDAC6 3708/4885HDAC3 2459/4885 |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | ATG7, BECN1, SQSTM1 | HDAC1 464/4885HDAC6 59/4885HDAC3 418/4885 |
| US-20150290168-A1 | CLASS IIA HDAC INHIBITORS FOR THE TREATMENT OF INFECTION | HDAC4, HDAC1, HDAC9 | HDAC1 2/4885HDAC6 10/4885HDAC3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.